Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Antifungal anthraquinones from *Saprosma fragrans*

D. N. Singh, a,c,* N. Verma, c S. Raghuwanshi, b P. K. Shukla b and D. K. Kulshreshtha a

a Medicinal and Process Chemistry Division, Central Drug Research Institute, Chattar Manzil Palace, Lucknow 226001, India
b Fermentation Technology Division, Central Drug Research Institute, Chattar Manzil Palace, Lucknow 226001, India
 c K. S. Saket Post Graduate College, Dr. R. M. L. Avadh University, Faizabad 224001, India

Received 7 April 2006; revised 7 June 2006; accepted 9 June 2006
Available online 7 July 2006

Abstract—A new 3,4-dihydroxy-1-methoxy anthraquinone-2-carboxaldehyde (1) together with a known anthraquinone, dammacanthal (2), were isolated from the chloroform fraction of the aerial part (whole plant without root) of *Saprosma fragrans*. The isolated anthraquinones (1) and (2) were found to exhibit antifungal activity against *Trichophyton mentagrophytes* and *Sporotrichum schenckii*. Their structures were established by chemical and spectral analysis.

© 2006 Elsevier Ltd. All rights reserved.

The clinical relevance of fungal diseases increases enormously due to the increasing of the immunocompromised host in the second half of the 20th century including individuals infected with HIV, transplant recipients and patients with cancer. 1,2 The fungal threat will continue to increase, as shown by the occurrence of aspergillosis in severe acute respiratory syndrome (SARS) 3 and by the inclusion of *Coccidioides immitis* as a potent agent of bioterrorism. 4 The crude mortality from opportunistic fungal infections still exceeds 50% in most human studies and has been reported to be as high as 95% in bone marrow transplant recipients infected with *Aspergillus* sp. 5 The adequate treatment of mycotic infections is difficult since fungi are eukaryotic organisms with a structure and metabolism that is similar to those of eukaryotic host. Furthermore, long-term treatment with commonly used antifungals, such as amphotericin-B, has toxic effects: ketoconazole, fluconazole and clotrimazole are limited in their spectrum and efficacy and use may result in strain resistance. 6,7 For this reason, there is a need for new active molecules which can serve as lead for further development in antifungal chemotherapy.

During our continuing efforts to identify antifungal leads from plant sources, *Saprosma fragrans* 8 was collected from Kerala (Silent Valley), India, on the western slope at the alt. 2000 ft. and identified by our Botany division of CDRI, Lucknow.

A preliminary biological screening of the ethanolic extract of the aerial part (whole plant without root) of this plant exhibited significant antifungal activity which was found to be localized in chloroform fraction. Further chromatographic purification leads to isolation of one novel 3,4-dihydroxy-1-methoxy anthraquinone-2-carboxaldehyde (1) along with a known anthraquinone (2). In this paper, we describe the isolation, structure elucidation and antifungal activity of 3,4-dihydroxy-1-methoxy anthraquinone-2-carboxaldehyde (1) and previously known anthraquinone, dammacanthal (2).

| Compound | R1    | R2  |
|----------|------|-----|
| 1        | CHO  | OH  |
| 1R       | CH2OH| OH  |
| 2        | CHO  | H   |

Air-dried plant material (10 kg) was pulverized and extracted with 95% ethanol (4× 15 L) for 24 h at room temperature. The whole extract was concentrated under reduced pressure by using rotatory evaporator at 50 °C and finally dried under vacuo to get solid mass coded as D002 (315 g). The crude ethanolic extract (145 g)
was macerated with n-hexane to get n-hexane-soluble fraction (F003, 2.5 g). The insoluble residue was partitioned between chloroform and water to give chloroform-soluble fraction (F004, 40 g) and aqueous portion. The aqueous portion was then partitioned with n-butanol to give n-butanol-(F005, 63 g) and water-soluble fraction (F006, 39 g). All these fractions were submitted for evaluation of antifungal activity against human pathogenic fungi. The chloroform fraction (F004) showed significant antifungal activity. The fraction F004 (15 g) was subjected to column chromatography by using n-hexane containing increasing amount of acetone as an eluent to give a fraction F007 n-hexane–acetone (9:1 v/v) in which activity was localized. The fraction F007 (7 g) was further subjected to repeated column chromatography by using benzene and increasing amount of methanol as an eluent to give two compounds 1 and 2. The compound 2 was identified as 3-hydroxy-1-methoxy anthraquinone-2-carboxaldehyde by comparison of their spectral data with those reported in the literature9–11 and the structure of the newly isolated compound 1 was elucidated as 3,4-dihydroxy-1-methoxy anthraquinone-2-carboxaldehyde by their detailed spectral and chemical analysis. Compound 1 was obtained as yellowish amorphous powder and crystallized in methanol acetone mixture, mp 273–275 °C. In IR spectrum of the compound a strong absorption band to anthraquinone nucleus, 12 signal at 1670, 1587 cm⁻¹ due to anthraquinone nucleus9,12,13 and at 1652 cm⁻¹ and 1640 cm⁻¹ due to the two chelated carbonyl groups. The 1H NMR spectrum of the compound (Table 1) showed a total 16 carbons. Their multiplicity assignment was made by DEPT experiment. It revealed the presence of 1 methyl, 5 methine and 10 quaternary carbons. Out of these signals at δ 127.5, 134.25, 134.35 and 127.5 assigned to four aromatic methines, signals at δ 180.4 and 182.8 for two carbonyl groups of anthraquinone nucleus,12,13 signal at δ 195 for aldehydic carbon, signals at δ 164.0, 164.5 and 164.09 to oxygenated aromatic carbons, signal at δ 119.0 to the aromatic quaternary carbon bearing aldehydic group and remaining signals at 117.0, 109.0, 134.0 and 133.0 to the aromatic quaternary carbons and the signal at δ 65.6 is due to methoxy carbon. All these spectral data suggested compound 1 to be 3,4-dihydroxy-1-methoxy anthraquinone-2-carboxaldehyde.

The isolated anthraquinones exhibited prominent antifungal activity as compared to the activity profile of the reported anthraquinones.17–19 Anthraquinone (1) exhibited antifungal activity with MIC values of 12.5 μg/ml against Trichophyton mentagrophytes and 25 μg/ml against S. schenckii. The MIC values observed were 1.56 μg/ml against T. mentagrophytes and 6.25 μg/ml against Sporothrix schenckii for anthraquinone 2. The isolated compounds had better activity than ethanolic extract. The clotrimazole served as a standard antifungal drug having MIC value of 0.39 μg/ml against T. mentagrophytes and 1.56 μg/ml against S. schenckii in the same assay. Bioassay was performed by 2-fold serial dilution method in Sabouraud’s dextrose broth. The spore suspension of 10⁶ and 10⁸ spores/ml was used for this purpose. The tests were performed at 28 °C and inhibition in growth of fungi, that is, MICs was recorded by visual observation after 24–72 h incubation.20,21 The details in vitro activity profile of the ethanolic extract, fractions and the compounds 1 and 2 against five human pathogenic fungi are given in Table 2.

In conclusion, we have identified a novel naturally occurring anthraquinone along with a known one displaying promising antifungal activity in vitro. Further, synthesis of these naturally occurring anthraquinones will help in the study of SAR. This may provide a lead molecule in developing a potent antifungal drug.

Table 1. ¹H and ¹³C data of compound 1 in CDCl₃ (200 MHz)

| Position | δH (J in Hz) | δC |
|----------|--------------|----|
| 1        | —            | 164.0 |
| 2        | —            | 119 |
| 3        | —            | 164.5 |
| 4        | —            | 164.09 |
| 5        | 8.24 (1H, d, J = 7.9 Hz) | 127.5 |
| 6        | 7.77–7.84 (2H, m) | 134.25 |
| 7        | 7.77–7.84 (1H, m) | 134.35 |
| 8        | 8.17 (1H, d, J = 7.9 Hz) | 127.5 |
| 9        | —            | 180.4 |
| 10       | —            | 182.8 |
| 9a       | —            | 117 |
| 4a       | —            | 109 |
| 8a       | —            | 134 |
| 10a      | —            | 133 |
| CHO      | 10.45 (1H, s) | 195 |
| OCH₃     | 4.10 (3H, s) | 65.6 |
| OH       | 13.06 (1H, s) | — |
| OH       | 12.07 (1H, s) | — |
Acknowledgments

Authors are thankful to Dr. B. N. Mehrotra of our Botany Division for collection and identification of the plant material and the staff of the RSIC, CDRI, Lucknow, for spectral data. The financial assistance from the Office of Novel Research, USA, is greatly acknowledged.

References and notes

1. Clark, T. A.; Hajjeh, R. A. Curr. Opin. Infect. Dis. 2002, 15, 569.
2. Hage, C. A.; Goldman, M.; Wheat, L. J. Eur. J. Med. Res. 2002, 7, 236.
3. Wang, H.; Ding, Y.; Li, X.; Yang, L.; Zhang, W.; Kang, W. N. Engl. J. Med. 2003, 349, 507.
4. Dixon, D. M. J. Appl. Microbiol. 2001, 91, 602.
5. Romaní, L. Nat. Rev. Immunol. 2004, 4, 11.
6. Wakabayashi, H.; Abe, S.; Teraguchi, S.; Hayasawa, H.; Yamaguchi, H. Antimicrob. Agents Chemother. 1998, 42, 1587.
7. Helmerhorst, E. J.; Reijnders, I. M.; Hof, W. V. T.; Smits, I. S.; Veerman, E. C. J.; Amerongen, A. V. N. Antimicrob. Agents Chemother. 1999, 43, 702.
8. Hooker, J. D. Flora Br. India 1978, 3, 193.
9. Murti, V. V. S.; Seshadri, T. R.; Sivakumaran, S. Indian J. Chem. 1972, 10, 246.
10. Thomson, R. H. Naturally Occurring Quinones; Academic Press: London, 1971, 365.
11. Kwanjai, K.; Somdej, K.; Ruchanee, P. J. Ethnopharmacol. 2005, 100, 284.
12. Itokawa, H.; Mihara, K.; Takeya, K. Chem. Pharm. Bull. 1983, 31, 2353.
13. Tessier, A. M.; Delaveau, P.; Champion, B. Planta Med. 1981, 41, 337.
14. Dosseh, C.; Tessier, A. M.; Delaveau, P. Planta Med. 1981, 43, 360.
15. Itokawa, H.; Qiao, Y.; Takeya, K. Phytochemistry 1989, 28, 3465.
16. Reduction of compound 1. The compound 1 (5 mg) was dissolved in ethanol (2 ml) and 5 mg NaBH₄ was added to the solution then stirred the reaction mixture at room temperature for 3 h and maintained the pH-5 of the reaction mixture with acetic acid and evaporated to dryness, then 2 ml water was added and extracted with chloroform. The chloroform layer gave the reduced product (1R). ¹H NMR (CDCl₃, 200 MHz) δ ppm: 13.06 (1H, s), 7.75–7.82 (2H, m), 8.13 (1H, d, J = 7.9 Hz), 8.23 (1H, d, J = 7.9 Hz), 4.0 (3H, s, OCH₃), 4.15 (2H, s, CH₂OH).
17. Shadomy, S.; Espinel-Ingroff, A. Susceptibility Testing of Antifungal Agents. In Manual of Clinical Microbiology; Lennett, E. H., Spaulding, E. H., Truant, J. P., Eds., 2nd ed.; American Society of Microbiology: Washington, DC, 1974; pp 569–574.
18. Agarwal, S. K.; Singh, S. S.; Verma, S.; Kumar, S. J. Ethnopharmacol. 2000, 72, 43.
19. Pagnocca, F. C.; Ribiero, S. B.; Tarkomian, V. L. V.; Hebling, M. J. A.; Bueno, O. C.; Silva, O. A.; Fernandez, J. B.; Vieira, P. C.; Silva, M. F. G. F.; Fereira, A. G. J. Chem. Ecol. 1996, 22, 1325.
20. Dhar, M. L.; Dhar, M.; Dhawan, B. N.; Mehrotra, B. N.; Ray, C. Indian J. Exp. Biol. 1968, 6, 232.
21. Ram, V. J.; Nath, M.; Shukla, P. K. Bioorg. Med. Chem. Lett. 1997, 7, 2137.

Table 2. In vitro antifungal activity (minimum inhibitory concentration µg/ml) of ethanolic extract (D002), fractions (F003-007) and compounds 1 and 2 against human fungal pathogens

| Code no. | Candida albicans | Cryptococcus neoformans | Sporothrix schenckii | Trichophyton mentagrophytes | Aspergillus fumigatus |
|----------|------------------|-------------------------|----------------------|---------------------------|----------------------|
| D002     | 250              | 125                     | 500                  | 62.5                      | NA                   |
| F003     | 500              | 125                     | NA                   | 62.5                      | 500                  |
| F004     | 125              | 62.5                    | 250                  | 15.6                      | 250                  |
| F005     | 250              | 125                     | NA                   | 62.5                      | 500                  |
| F006     | 250              | 125                     | NA                   | 62.5                      | 500                  |
| F007     | 62.5             | 62.5                    | 62.5                 | 6.6                       | 125                  |
| Compound 1| 50               | 50                      | 25                   | 12.5                      | >100                 |
| Compound 2| 50               | 12.5                    | 6.25                 | 1.56                      | 50                   |
| Clotrimazole | 3.1            | 0.09                    | 1.56                 | 0.39                      | 1.56                 |

NA, Inactive at the tested concentration between 1.56–500 µg/ml.